Aim: To counteract Hepatitis C viral lethality, an insect recombinant DNA vaccine of Hepatitis C virus genotype 4 subtype 4a was developed using E1, E2, and Capsid protein structural proteins. Methodology: In the current study, HCV-like particles vaccinations composed of coherent structural proteins (E1, E2, and Capsid protein) of HCV were created in an expression host insect cell line employing a Baculovirus expression vector. Recombinant Baculovirus VLPs were produced by modified bac-to-bac site-specific transposition and purified via affinity chromatography. The current vaccine's immunogenicity was assessed in preclinical animal testing on transgenic mice, followed by clinical trials stages 1/2. Results: The current vaccine achieved 71% efficacy in animal models and 63% efficacy throughout stages 1-2 of human clinical trials. They have little biological influence and have few negative implications. The effect lingered for a time. An HCV-like particle immunization improved both humoral and cell-mediated protection against hepatitis C virus infection. Advantages: It is not feasible to revert to virulence.Cons: Because the vaccine virus cannot be expelled or transferred to people who have not received the immunization, it does not contribute to herd immunity against this viral infection. Conclusions: The immunization proved effective in avoiding HCV virus infection in the current study. To counteract the HCV virus's rapid mutation rate, it must be updated on a frequent basis.
Kassab, M. (2023). The exploitation of Hepatitis C virus-like particles vaccine against genotype 4 by bioinformatics. International Journal of Health Sciences (Egypt), 1(3), 75-83. doi: 10.21608/ijhegy.2023.202614.1016
MLA
Mohammed M Kassab. "The exploitation of Hepatitis C virus-like particles vaccine against genotype 4 by bioinformatics". International Journal of Health Sciences (Egypt), 1, 3, 2023, 75-83. doi: 10.21608/ijhegy.2023.202614.1016
HARVARD
Kassab, M. (2023). 'The exploitation of Hepatitis C virus-like particles vaccine against genotype 4 by bioinformatics', International Journal of Health Sciences (Egypt), 1(3), pp. 75-83. doi: 10.21608/ijhegy.2023.202614.1016
VANCOUVER
Kassab, M. The exploitation of Hepatitis C virus-like particles vaccine against genotype 4 by bioinformatics. International Journal of Health Sciences (Egypt), 2023; 1(3): 75-83. doi: 10.21608/ijhegy.2023.202614.1016
', './data/ijhegy/coversheet/321696090111.jpg'))
View on SCiNiTO